Layla review

The first month is not the continuing price

Layla's monthly plan cards advertise $99 for the first month of compounded semaglutide or tirzepatide. The ordinary prices printed alongside them are $199 monthly for semaglutide and $299 for tirzepatide. Those standing amounts are the appropriate starting point for a continuing budget. A buyer should not multiply the introductory $99 by several months and treat the result as the cost of staying on either medication.

The difference between the molecules becomes visible after the promotion: the ordinary tirzepatide amount is $100 above semaglutide. That financial distinction does not establish which medicine is suitable or whether changing a prescription is sensible. Ask the prescriber to identify the proposed treatment first, then request its supply, dose and renewal charge together. The first-month promotion can be counted afterward as a separate initial saving, if its eligibility conditions apply.

The quarterly labels need clarification

Layla also displays quarterly options at $297 and $449, but labels them per month. Those labels cannot be reconciled with its cheaper monthly plans from the public information alone. The figures should not silently be divided by three and presented as confirmed monthly equivalents. Nor should they be assumed to be three installments. Ask for the total collected, the period purchased and the charge schedule for the actual selected option.

This matters because a plan named quarterly can describe several different arrangements: advance payment for a supply, a commitment paid in installments or a renewal every three months. The page needs to identify which applies. A patient who wants to reassess after an initial prescription should understand that commitment before choosing a longer offer. The ability to stop future renewal, if offered, would not by itself establish a refund for an already purchased period.

Named practices help identify the clinical relationship

Layla names operating entities including Beluga Health, P.A. and Pennsylvania Medical, P.C. as prescribing practices. Those names provide a more concrete starting point than an anonymous reference to licensed providers. They do not establish which clinician will manage your particular prescription. Ask which practice serves your state, how the prescriber reviews changes and where follow-up questions are sent after the first supply arrives.

The distinction between platform, clinician and dispenser is useful when something needs correcting. A billing question, a clinical symptom and a pharmacy-label question may require different contacts. Before paying, ask how the service routes each one and how a patient obtains the dispensing pharmacy's details. Public corporate disclosure improves accountability, but it is not evidence that a requested medicine will be prescribed or that the consultation includes a particular specialist's assessment.

Judge the offer rather than the countdown

The earlier public offer displayed a Cyber Week banner and a countdown at zero during August. That historical presentation is a reason to read the actual selected terms carefully, rather than an assertion that the same banner remains live today. A deadline graphic does not establish a medical reason to rush, a genuine ending date for every promotion or the amount due on the next renewal.

Layla does not publish a complete state list on its public site. Confirm location, formulation and clinician access before planning a transition from another prescription. The service is easiest to compare using the ordinary $199 and $299 monthly amounts, with the initial discount and unresolved quarterly offer kept separate. A complete purchase decision also needs the cancellation process and any refund limits. Those terms are more important to financial flexibility than the fact that the opening month looks inexpensive.